Literature DB >> 23561234

A prevalence study of urinary tract infections in acute relapse of schizophrenia.

Brian J Miller1, Krystle L Graham, Chelsea M Bodenheimer, Nick H Culpepper, Jennifer L Waller, Peter F Buckley.   

Abstract

OBJECTIVE: Schizophrenia is associated with immune abnormalities and increased mortality from infectious diseases. The aim of this study was to examine whether acute relapse of schizophrenia was associated with urinary tract infection (UTI), in comparison with controls, after controlling for potential confounding factors.
METHOD: In a prevalence study conducted from January 2010 to April 2012 at Georgia Health Sciences University Medical Center, Augusta, we recruited 136 adult subjects (mean age = 42.8 years): 57 inpatients with an acute relapse of DSM-IV schizophrenia, 40 stable outpatients with DSM-IV schizophrenia, and 39 healthy controls from the community. Urinary tract infection was defined as having positive leukocyte esterase and/or positive nitrites on urinalysis and having ≥ 5 leukocytes per high-powered field (implies 5-10 or more) on urine microscopy. Determination of UTI status was made for each subject, and analyses were performed to examine the association between UTI and acute relapse of schizophrenia.
RESULTS: 35% of acutely relapsed subjects, versus 5% of stable outpatients and 3% of controls, had a UTI (P < .001). Only 40% of subjects in the acute relapse group classified as having a UTI were treated with antibiotics during hospitalization. After analyses were controlled for gender and smoking status, subjects in the acute relapse group were almost 29 times more likely to have a UTI than controls (odds ratio = 28.97; 95% CI, 3.44-243.85; P = .002). There was no statistically significant association with UTI among the stable outpatients versus controls.
CONCLUSIONS: Our finding of an association between an increased prevalence of UTI and acute psychotic relapse warrants replication in other samples. The mechanism of this association remains unclear. The results also highlight the potential importance of monitoring for comorbid UTI in acutely relapsed patients with schizophrenia. © Copyright 2013 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23561234     DOI: 10.4088/JCP.12m08050

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  18 in total

Review 1.  Inflammation and schizophrenia.

Authors:  Brian Kirkpatrick; Brian J Miller
Journal:  Schizophr Bull       Date:  2013-09-26       Impact factor: 9.306

Review 2.  Inflammation and the two-hit hypothesis of schizophrenia.

Authors:  Keith A Feigenson; Alex W Kusnecov; Steven M Silverstein
Journal:  Neurosci Biobehav Rev       Date:  2013-11-15       Impact factor: 8.989

Review 3.  Is there a role for immune-to-brain communication in schizophrenia?

Authors:  Golam M Khandaker; Robert Dantzer
Journal:  Psychopharmacology (Berl)       Date:  2015-06-04       Impact factor: 4.530

4.  Exploring the Effectiveness of Team-based Enablement Interventions to Improve Antibiotic Prescribing within a Psychiatric Hospital.

Authors:  Emily E Leppien; Tammie Lee Demler; Eileen Trigoboff
Journal:  Innov Clin Neurosci       Date:  2019-05-01

5.  Evaluating the Hypothesis That Schizophrenia Is an Inflammatory Disorder.

Authors:  Brian J Miller; David R Goldsmith
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

6.  Meta-Analysis of Anti-Toxoplasma gondii IgM Antibodies in Acute Psychosis.

Authors:  Joel M Monroe; Peter F Buckley; Brian J Miller
Journal:  Schizophr Bull       Date:  2014-11-09       Impact factor: 9.306

7.  Willingness to be vaccinated against COVID-19 is equal in individuals with affective disorders and healthy controls.

Authors:  Frederike T Fellendorf; Nina Bonkat; Martina Platzer; Elena Schönthaler; Michaela Ratzenhofer; Susanne A Bengesser; Nina Dalkner; Eva Z Reininghaus
Journal:  Vaccine X       Date:  2022-06-20

Review 8.  Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions.

Authors:  Brian J Miller; David R Goldsmith
Journal:  Neuropsychopharmacology       Date:  2016-09-22       Impact factor: 7.853

9.  Mortality in schizophrenia: clinical and serological predictors.

Authors:  Faith Dickerson; Cassie Stallings; Andrea Origoni; Jennifer Schroeder; Sunil Khushalani; Robert Yolken
Journal:  Schizophr Bull       Date:  2013-08-13       Impact factor: 9.306

10.  Complement C4 associations with altered microbial biomarkers exemplify gene-by-environment interactions in schizophrenia.

Authors:  Emily G Severance; Flora Leister; Ashley Lea; Shuojia Yang; Faith Dickerson; Robert H Yolken
Journal:  Schizophr Res       Date:  2021-02-23       Impact factor: 4.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.